Medicare patients admitted to hospitals with higher readmission rates are more likely to have characteristics associated with a higher probability of readmission, according to a study published online today by JAMA Internal Medicine. “This finding suggests that Medicare is penalizing hospitals to a large extent based on the patients they serve,” the study concludes. The authors found 22 patient characteristics that significantly predicted readmission when added to standard Hospital Readmissions Reduction Program adjustments of hospital readmission rates, and 17 of these were distributed differently between hospitals in the highest and lowest quintiles of publicly reported readmission rates. For example, patients admitted to the highest quartile had more chronic conditions, less education, fewer assets, worse self-reported health status, more depressive symptoms, worse cognition and physical functioning, and more difficulties with daily living activities. The difference in readmission risk between hospitals in the highest and lowest quintiles fell by 48% after adjusting for all patient characteristics assessed. For more on the study, see today’s AHASTAT blog post.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services has extended the deadline for submitting third-quarter data to the Post-Acute Care Quality Reporting Program.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Hospitals and clinicians are seeing fewer flu patients this season than in other recent years, the Centers for Disease Control and Prevention reports.
Insights and Analysis
Please consider applying for the award and sharing how your organization is improving health equity and value.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…